| Audience | Patients, caregivers, prescribers, and cannabis-science readers interested in safer medical cannabis use |
| Primary Topic | UK medical cannabis prescriptions, product sourcing, and high-risk use |
| Source | Read the full source |
UK Medical Cannabis Use: What a New National Survey Found
A July 31, 2026 national repeat cross-sectional study surveyed 4,414 UK residents who had used cannabis in the prior year. Prescribed respondents more often reported frequent use of several processed products and screening-positive high-risk use. These are associations, not proof that prescribing caused risky use.
| Study Type | National repeat cross-sectional surveys conducted in 2023 and 2024 |
| Population | 4,414 UK participants aged 16 to 65 who reported cannabis use in the past 12 months |
| Comparison Groups | Medical use with a prescription, medical use without a prescription, and no medical use |
| Prescribed Medical Use | 12.9% of respondents |
| Medical Use Without Prescription | 35.9% of respondents |
| No Medical Use | 51.2% of respondents |
| Source Finding | Only 10.9% of respondents with prescriptions reported obtaining all cannabis from a prescription |
| Product Finding | Prescribed respondents had higher adjusted probabilities of frequent use across several processed product categories |
| High-Risk Screen | Prescribed respondents had a higher probability of screening positive for high-risk use, adjusted risk ratio 3.09, 95% CI 2.51 to 3.79 |
| Major Limitation | Cross-sectional self-report data cannot establish temporality, causation, or whether prescribing itself changed risk |
| Journal | Psychological Medicine |
| Published | July 31, 2026 |
| Authors | Elle Wadsworth, David Hammond, and Tom P. Freeman |
| PMID / DOI | 42535284 / 10.1017/S0033291726105327 |
Researchers analyzed national repeat cross-sectional surveys from 2023 and 2024. Participants were UK residents aged 16 to 65 who reported cannabis use within the prior 12 months.
The analysis compared medical use with a prescription, medical use without a prescription, and nonmedical use. It examined sources, product types, frequent product use, and a screening threshold for high-risk use.
Medical use without a prescription was more common than prescribed medical use in this sample. Among respondents with prescriptions, only 10.9% reported obtaining all cannabis through a prescription.
After adjustment, prescribed respondents more often reported frequent use of drops, capsules, vape oils, edibles, drinks, solid concentrates, hash or kief, and topicals. They also had a higher probability of screening positive for high-risk use.
The surveys measured exposure and outcomes at the same general time. They cannot establish whether prescribing preceded higher-risk patterns, followed them, or simply identified people with more complex or intensive cannabis use.
Self-report, selection into the survey, differences in health status, symptom burden, product access, and other unmeasured factors may influence the observed associations.
The sourcing result is clinically important because prescribed patients may also use cannabis obtained elsewhere. Product composition, potency, route, frequency, and labeling may differ across sources.
A useful clinical history should therefore cover every cannabis product, not only the prescribed item listed in a medication record.
Prescribing encounters can include structured discussion of treatment goals, total cannabis exposure, product potency, impairment, tolerance, withdrawal, unsuccessful efforts to reduce use, interactions, and adverse effects.
A positive high-risk-use screen is not itself a diagnosis. It is a reason for further assessment, shared decision-making, and proportionate follow-up.
Medical and nonmedical cannabis categories can overlap in real life. People may use multiple products for multiple reasons and obtain them through several channels, which complicates both exposure measurement and clinical counseling.
Future longitudinal research should measure baseline risk, symptom severity, product potency, dose, source, changes over time, and clinically assessed cannabis use disorder before and after prescribing.
The most useful message is not that prescriptions are dangerous. It is that a prescription label can create false reassurance if the clinician never asks what else the patient is using.
A careful medical cannabis visit should connect therapeutic goals with a complete product inventory, an impairment and dependence screen, and a plan for monitoring benefit and harm over time.
How to Interpret This UK Medical Cannabis Safety Signal
This study identifies a clinically important pattern without proving its cause.
The most responsible reading separates what was measured from what still needs longitudinal confirmation.
A Four-Step Reading Frame
Evidence type
This is a repeat cross-sectional observational study, not a randomized trial or longitudinal causal analysis.
Population
The sample includes UK residents aged 16 to 65 who used cannabis in the prior year, not all UK patients or all prescription recipients.
Outcome meaning
A screening-positive high-risk-use result signals need for assessment; it is not equivalent to a confirmed cannabis use disorder diagnosis.
Clinical use
The findings support fuller product and risk histories during prescribing, while leaving treatment decisions individualized.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
List Every Product and Source
A prescription may be only one part of a person’s cannabis exposure.
Bring a complete list of products, routes, sources, frequency, and effects to clinical visits.
Prescribing Needs Active Monitoring
Medication reconciliation should include nonprescribed cannabis and processed products.
Screening should be paired with assessment of goals, benefit, impairment, tolerance, withdrawal, and function.
Selection May Explain Part of the Signal
People who obtain prescriptions may have heavier use, greater symptom burden, or more complex histories before prescribing.
Cross-sectional adjustment cannot fully resolve those differences.
Screening Is Not Diagnosis
A high-risk-use threshold is useful for identifying people who may need further review.
It should not be reported as a confirmed disorder without diagnostic assessment.
Real-World Use Blurs Legal Categories
Cannabis exposure often spans multiple products and sources.
This study adds current UK data showing why prescribed and nonprescribed use cannot always be treated as separate worlds.
Ask About Potency, Route, and Function
Product names alone do not define exposure.
Useful follow-up includes potency, dose, frequency, driving or work impairment, interactions, and progress toward the treatment goal.
Longitudinal Evidence Is the Next Step
Researchers need measurements before and after prescribing with repeated assessment over time.
Product-level exposure and clinically assessed outcomes would help clarify direction and mechanism.
Access and Surveillance Should Develop Together
Legal access can improve oversight only when systems capture real product use and adverse outcomes.
Policy should support honest reporting, consistent product information, and nonpunitive clinical screening.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
Frequently Asked Questions
Does this study prove that medical cannabis prescriptions cause high-risk use?
No. The cross-sectional study found an adjusted association, but it cannot establish which came first or prove causation.
How many people were included?
The analysis included 4,414 UK participants aged 16 to 65 who reported cannabis use in the prior 12 months.
What did the study mean by medical cannabis use?
Researchers separated respondents reporting medical use with a prescription, medical use without a prescription, and no medical use.
Did everyone with a prescription obtain all cannabis through that prescription?
No. Only 10.9% of prescribed respondents reported obtaining all of their cannabis from a prescription.
Is a positive high-risk-use screen the same as a cannabis use disorder diagnosis?
No. A screening result identifies possible risk and should be followed by appropriate clinical assessment.
Which products were more frequently reported by prescribed respondents?
The abstract reports higher adjusted probabilities for frequent use of drops, capsules, vape oils, edibles, drinks, solid concentrates, hash or kief, and topicals.
Can the findings be generalized outside the UK?
Not automatically. Laws, prescribing systems, product markets, and patient populations differ across countries.
What should patients discuss with a prescriber?
Discuss every cannabis source and product, potency, frequency, treatment goals, benefits, impairment, adverse effects, interactions, tolerance, and withdrawal.
What is the study's biggest limitation?
Its cross-sectional self-report design cannot establish temporality or determine whether prescribing changed risk.
What is the practical takeaway?
Medical cannabis care should include a complete exposure history and ongoing benefit-risk monitoring rather than relying on prescription status alone.
